Tylosin is a macrolide antibiotic produced by fermentation of Streptomyces fradiae. The veterinary-grade API for tablets, injections, capsules, powders, granules, premixes, and solutions is supplied as tylosin base, tylosin tartrate, and tylosin phosphate; each salt differs in aqueous solubility, pH sensitivity, thermal stability, and regulatory status. The downstream applications documented below are restricted to authorized or extralabel veterinary indications in major production markets. No zootechnical growth-promotion claim is included for jurisdictions where antimicrobial performance uses are prohibited. The scenarios are organized by target species and dosage form, with each section addressing the required compliance standard, formulation addition ratio, downstream production process, and terminal finished product type.

Swine Dysentery and Proliferative Enteropathy Control Under Veterinary Feed Directive Conditions

Tylosin phosphate is incorporated into complete swine rations as a medicated feed premix for treatment and control of swine dysentery associated with Brachyspira hyodysenteriae and porcine proliferative enteropathy associated with Lawsonia intracellularis. The United States legal basis is 21 CFR 558.625 with veterinary feed directive status under 21 CFR 558.6, meaning the feed mill must receive and retain a lawful VFD before mixing the batch. In the European Union, tylosin in medicated feed is handled under Regulation (EU) 2019/6, and feed hygiene requirements under Regulation (EC) No 183/2005 apply to the mixing line; tylosin is not authorized as a zootechnical feed additive in the EU. The formulation addition rate is calculated on a tylosin activity basis: a 10% tylosin phosphate premix is included at 0.1–1.0 kg per ton to deliver 10–100 g tylosin per ton complete feed, with the 100 g/ton rate applied to swine dysentery for a defined treatment period typically not exceeding 6 weeks and subject to regional withdrawal periods. At the feed mill, the API is first pre-blended with calcium carbonate, mineral oil, or rice hulls in a horizontal ribbon mixer operating at 30–40 rpm and a fill volume of 60–70% of rated capacity; geometric dilution is performed in at least three stages from 10% to 1% to 0.1% before the intermediate premix enters the final mixer. Carrier particle size is matched to the API with a D50 below 75 µm to control segregation during bucket elevator transfer and auger conveying. When the finished feed is pelleted, conditioning at 75–85°C for 20–40 s is common on commercial lines, but published degradation data for this specific temperature-time configuration is limited and each mill should confirm recovered potency. A production-scale limitation observed in bulk premix handling is that residual moisture in the carrier above 5% can increase tylosin phosphate hydrolysis during storage in warm humid bins above 30°C and 60% relative humidity. Terminal finished products include meal, steam-pelleted complete feeds, and extruded nursery diets labeled for swine dysentery or proliferative enteropathy control.

For broiler and turkey flocks where feed intake collapses during acute respiratory outbreaks caused by Mycoplasma gallisepticum or complicating Clostridium perfringens enteritis, tylosin tartrate soluble powder is selected for mass medication through drinking-water lines because oral uptake continues even when feed is refused. The United States regulatory basis is the FDA-approved label for tylosin tartrate soluble powder, with conditions outside approved species governed by 21 CFR Part 530; in the European Union, national marketing authorizations under Regulation (EU) 2019/6 define species-specific indications and withdrawal periods, and maximum residue limits for tylosin are listed in Commission Regulation (EU) No 37/2010. The dosing calculation is performed on a bodyweight basis at 10–20 mg tylosin activity per kg body weight per day, adjusted to measured daily water consumption; final drinking-water concentration is commonly 0.25–1.0 g tylosin per liter, with the label dilution table as the binding reference. A 100 g sachet is typically dissolved into 100–400 L of final drinking water depending on species, age, and water intake. The powder is dissolved at 20–25°C under low-shear agitation in a clean plastic or stainless steel tank; water pH is maintained between 5.5 and 7.0 because alkaline hydrolysis opens the macrolide lactone ring, and chlorinated water intended for stock solutions held longer than 4 h should be dechlorinated or used immediately. Terminal finished forms are 100 g and 500 g foil sachets, 1 kg and 5 kg jars, and 25 kg multi-layer foil-lined bulk bags containing freely water-soluble tylosin tartrate powder; the stock solution is typically used within 24 h to avoid potency loss.

Sterile injectable manufacturing of tylosin base at 200 mg/mL is used for treatment of bovine respiratory disease, swine arthritis, and infectious foot rot where the macrolide must be administered by intramuscular injection and immediate systemic exposure is required. Compliance for approved injectable products in the United States references 21 CFR 522.2640 for tylosin injection and requires release testing under USP <71>, USP <85>, and USP <788>; in the European Union, the Ph. Eur. monograph for tylosin for veterinary use and Regulation (EU) 2019/6 govern the finished product. The formulation addition rate is expressed as finished concentration: 50 mg/mL and 200 mg/mL tylosin base per vial are the common commercial strengths, with the API as the sole active ingredient and the vehicle composed of propylene glycol or another non-aqueous co-solvent system selected to maintain solubility and reduce hydrolysis. During compounding, the vehicle is heated to 30–40°C in a jacketed stainless steel vessel under continuous top-mounted agitation; tylosin base is added slowly to avoid clumping, and the bulk solution is blanketed with nitrogen to limit oxidative degradation of the unsaturated macrolide lactone. The bulk solution is filtered through a 0.22 µm PVDF or PES membrane into a sterile holding vessel and filled aseptically into depyrogenated Type I glass vials at fill volumes of 50 mL, 100 mL, 250 mL, or 500 mL. Terminal steam sterilization is generally avoided because heat exposure accelerates lactone ring degradation; aseptic filtration is the terminal sterilization step, which makes environmental monitoring data from the filling suite part of batch release. Terminal finished products are sterile injectable solutions for intramuscular administration, sealed with chlorobutyl rubber stoppers and aluminum crimp caps.

What Limits Blend Uniformity When Tylosin Phosphate Is Step-Diluted Into Feedlot Rations?

Feedlot cattle receive tylosin phosphate for reduction of liver abscesses caused by Fusobacterium necrophorum and Trueperella pyogenes in high-grain finishing rations. The U.S. legal basis is 21 CFR 558.625, and the feed must be manufactured under a veterinary feed directive; in the European Union, tylosin in bovine medicated feed is subject to Regulation (EU) 2019/6 and is not authorized as a performance-enhancing feed additive. The feeding rate is 60–90 mg/head/day, which corresponds to approximately 8–10 g/ton dry matter when cattle consume 9–10 kg dry matter per head daily. To achieve this low inclusion without segregation, a 10% tylosin phosphate premix is step-diluted first to 1% with soybean hulls or ground corn, then passed through a micro-ingredient skid or separate ingredient hopper before entering the final total mixed ration mixer. Field-scale horizontal twin-ribbon mixers with a mixing time of 3–5 min after the last ingredient and a fill level of 70–80% can achieve a coefficient of variation for tylosin below 10% when the intermediate premix particle size is below 150 µm and the bulk density difference between premix and ration is less than 15%. Pelleted finishing supplements are conditioned at 70–80°C with 30–45 s retention on many light-density feed lines, but recovery data should be verified if the line uses conditioning above 85°C. Terminal finished products are pelleted finishing supplements, loose mineral mixes, and total mixed rations delivered to feed bunks.

When commercial oral tablets are unavailable, veterinary pharmacies and licensed compounding facilities use tylosin base or tylosin tartrate to prepare capsules or compressed tablets for dogs with chronic enteropathy and suspected clostridial overgrowth. The United States legal basis is extralabel use under 21 CFR Part 530 and nonsterile compounding standards under USP <795>; in the European Union, the prescribing cascade under Regulation (EU) 2019/6 and national implementing rules governs extralabel compounding for companion animals. The dose is commonly 10–25 mg/kg body weight every 12–24 h, with 10 mg/kg twice daily used in published canine chronic enteropathy protocols; compounded capsule strengths of 25 mg, 50 mg, 100 mg, and 200 mg are prepared. Processing uses geometric dilution: the API is passed through a 40-mesh screen to break lumps, blended with lactose monohydrate in a V-blender or trituration mortar at 20–25 rpm for 20 min, and filled into hard gelatin capsules on a semi-automatic capsule machine with weight uniformity tested under USP <905>. Moisture content is kept below 3% and desiccant is included because tylosin tartrate is hygroscopic and hydrolytically sensitive in the presence of free water. Terminal products are capsules, small compressed tablets, or flavored oral suspensions; the bitter taste of tylosin makes capsules preferred over suspensions for long-term administration in dogs.

If Tylosin Tartrate Is Reconstituted in Farm Water Systems, pH Drift Determines Potency

Swine herds with depressed feed intake during acute enteric disease are medicated with tylosin tartrate granulated powders that dissolve in drinking water, delivering the drug via nipple drinkers or proportioner-controlled header tanks. The United States approved use for tylosin tartrate in swine water medication falls under the label for tylosin soluble powder; in the European Union, national authorizations under Regulation (EU) 2019/6 define the legal withdrawal interval and maximum residue limit compliance under Commission Regulation (EU) No 37/2010. The addition rate is calculated at 10–20 mg tylosin activity per kg body weight per day; final medicated water concentration is generally 0.25–1.0 g tylosin per liter depending on measured water intake and drinker type, and the label dilution table provides the required stock solution mass for proportioner pumps set at 1:128 or 1:200. Granulation is performed in a fluidized-bed granulator with tylosin tartrate, maltodextrin, and a povidone binder; inlet air temperature is set at 50–60°C, spray rate is adjusted to maintain product temperature below 40°C, and the dried granules are sieved to 150–710 µm with a loss-on-drying specification of 2.0–4.0%. The granules are filled into 100 g, 500 g, and 1 kg foil-lined sachets or 25 kg bulk bags. Water pH above 7.5 accelerates lactone ring opening and should be corrected with a buffer system or the holding time should be limited to 12 h; strong oxidizers, hypochlorite sanitizers, and acidic mineral dosing in the same stock tank are incompatible with tylosin tartrate. Terminal finished products are water-soluble granules, oral solution concentrates, and bulk powder for farm medicator systems.